Skip to main content
Premium Trial:

Request an Annual Quote

Asuragen, Life Technologies Ink MDx Alliance

NEW YORK (GenomeWeb News) – Asuragen and Life Technologies have entered into an exclusive agreement to develop and commercialize a molecular diagnostic test to aid physicians in monitoring and treating patients with chronic myeloid leukemia.

Asuragen's BCR/ABL1 assay will simultaneously detect and quantify BCR/ABL1 fusion transcripts (b2a2, b3a2, and e1a2) in a single reaction, Austin, Texas-based Asuragen said. The BCR/ABL1 fusion transcripts are present in roughly 95 percent of CML and 25 percent to 30 percent of patients with acute lymphoblastic leukemia, the firm added.

Monitoring the level of these transcripts may prove helpful in prognosing and managing treatment with the drugs imatinib (Gleevec), sunitinib (Sutent), and dasatinib (Sprycell), Asuragen said.

Under terms of the agreement, Asuragen will pursue CE marked-IVD registration in Europe and regulatory clearance in the US. The test will be distributed by Life Technologies and run exclusively on Applied Biosystems/ 7500 Fast Dx Real-Time PCR Instrument. Financial and further terms were not disclosed.

Asuragen President Rollie Carlson said in a statement that he believes Life Technologies' "strong molecular instrumentation offerings and broad commercialization capabilities will lead to adoption of this test throughout the world."

The Scan

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.

Fragile X Syndrome Mutations Found With Comprehensive Testing Method

Researchers in Clinical Chemistry found fragile X syndrome expansions and other FMR1 mutations with ties to the intellectual disability condition using a long-range PCR and long-read sequencing approach.

Team Presents Strategy for Speedy Species Detection in Metagenomic Sequence Data

A computational approach presented in PLOS Computational Biology produced fewer false-positive species identifications in simulated and authentic metagenomic sequences.

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.